Due to the crucial role played by active JAK2 in tumor cell transformation and proliferation, as well as on the increased prevalence of the JAK2V617F mutation in MPNs, JAK2 has become a potential molecular target for therapeutic intervention in MPN and other malignancies associated with abnormal JAK2-STAT signaling. The gene discussed is SOAT1; the disease is myeloproliferative neoplasm.